ACTH: The forgotten therapy

Seminars in Immunology

Volumn 27, Issue 3, 2015, Pages 216-226

  Montero Melendez, Trinidad ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ACTH; Drug discovery; GPCR; Inflammation; Melanocortin; Pro resolving mediator

Indexed keywords

CORTICOTROPIN; G PROTEIN COUPLED RECEPTOR; LIGAND; MELANOCORTIN; MELANOCORTIN RECEPTOR; ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG FORMULATION; HUMAN; INFLAMMATION; NONHUMAN; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; AMINO ACID SEQUENCE; ARTHRITIS, RHEUMATOID; HOMEOSTASIS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; MOLECULAR GENETICS; MULTIPLE SCLEROSIS; PATHOLOGY;

ADRENOCORTICOTROPIC HORMONE; AMINO ACID SEQUENCE; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; HOMEOSTASIS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; RECEPTORS, MELANOCORTIN; SIGNAL TRANSDUCTION;

EID: 84937523269     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.02.003     Document Type: Review

References (100)

1. Qin C., Zhang C., Zhu F., Xu F., Chen S.Y., Zhang P., et al. Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Res 2014, 42:D1118-D1123.
2. Liu Z., Fang H., Reagan K., Xu X., Mendrick D.L., Slikker W., et al. In silico drug repositioning: what we need to know. Drug Discov Today 2013, 18:110-115.
3. Hench P.S., Kendall E.C., Slocumb C.H., Polley H.F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann Rheum Dis 1949, 8(2):97-104.
4. Hench P.S., Kendall E.C., Slocumb C.H., Polley H.F. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic) 1950, 85:545-666.
5. Getting S.J., Christian H.C., Flower R.J., Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002, 46:2765-2775.
6. Cone R.D. Studies on the physiological functions of the melanocortin system. Endocr Rev 2006, 27:736-749.
7. Liem E.B., Lin C.M., Suleman M.I., Doufas A.G., Gregg R.G., Veauthier J.M., et al. Anesthetic requirement is increased in redheads. Anesthesiology 2004, 101:279-283.
8. Getting S.J. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006, 111:1-15.
9. Dores R.M. Adrenocorticotropic hormone, melanocyte-stimulating hormone, and the melanocortin receptors: revisiting the work of Robert Schwyzer: a thirty-year retrospective. Ann NY Acad Sci 2009, 1163:93-100.
10. Ollmann M.M., Wilson B.D., Yang Y.K., Kerns J.A., Chen Y., Gantz I., et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997, 278:135-138.
11. Yang Y.K., Ollmann M.M., Wilson B.D., Dickinson C., Yamada T., Barsh G.S., et al. Effects of recombinant agouti-signaling protein on melanocortin action. Mol Endocrinol 1997, 11:274-280.
12. Buch T.R., Heling D., Damm E., Gudermann T., Breit A. Pertussis toxin-sensitive signaling of melanocortin-4 receptors in hypothalamic GT1-7 cells defines agouti-related protein as a biased agonist. J Biol Chem 2009, 284:26411-26420.
13. Garcia-Borron J.C., Sanchez-Laorden B.L., Jimenez-Cervantes C. Melanocortin-1 receptor structure and functional regulation. Pigm Cell Res/Sponsored by Eur Soc Pigm Cell Res Int Pigm Cell Soc 2005, 18:393-410.
14. Sturm R.A. Skin colour and skin cancer - MC1R, the genetic link. Melanoma Res 2002, 12:405-416.
15. Xing Y., Parker C.R., Edwards M., Rainey W.E. ACTH is a potent regulator of gene expression in human adrenal cells. J Mol Endocrinol 2010, 45:59-68.
16. Loos R.J., Lindgren C.M., Li S., Wheeler E., Zhao J.H., Prokopenko I., et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008, 40:768-775.
17. Chen W., Kelly M.A., Opitz-Araya X., Thomas R.E., Low M.J., Cone R.D. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997, 91:789-798.
18. Lee D.J., Taylor A.W. Both MC5r and A2Ar are required for protective regulatory immunity in the spleen of post-experimental autoimmune uveitis in mice. J Immunol 2013, 191:4103-4111.
19. Catania A., Gatti S., Colombo G., Lipton J.M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004, 56:1-29.
20. Kroeze W.K., Sheffler D.J., Roth B.L. G-protein-coupled receptors at a glance. J Cell Sci 2003, 116:4867-4869.
21. Reiter E., Ahn S., Shukla A.K., Lefkowitz R.J. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacool Toxicol 2012, 52:179-197.
22. Herraiz C., Journe F., Abdel-Malek Z., Ghanem G., Jimenez-Cervantes C., Garcia-Borron J.C. Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. Mol Endocrinol 2011, 25:138-156.
23. Chai B., Li J.Y., Zhang W., Ammori J.B., Mulholland M.W. Melanocortin-3 receptor activates MAP kinase via PI3 kinase. Regul Pept 2007, 139:115-121.
24. Chai B., Li J.Y., Zhang W., Newman E., Ammori J., Mulholland M.W. Melanocortin-4 receptor-mediated inhibition of apoptosis in immortalized hypothalamic neurons via mitogen-activated protein kinase. Peptides 2006, 27:2846-2857.
25. Janes M.E., Chu K.M., Clark A.J., King P.J. Mechanisms of adrenocorticotropin-induced activation of extracellularly regulated kinase 1/2 mitogen-activated protein kinase in the human H295R adrenal cell line. Endocrinology 2008, 149:1898-1905.
26. Konda Y., Gantz I., DelValle J., Shimoto Y., Miwa H., Yamada T. Interaction of dual intracellular signaling pathways activated by the melanocortin-3 receptor. J Biol Chem 1994, 269:13162-13166.
27. Newman E.A., Chai B.X., Zhang W., Li J.Y., Ammori J.B., Mulholland M.W. Activation of the melanocortin-4 receptor mobilizes intracellular free calcium in immortalized hypothalamic neurons. J Surg Res 2006, 132:201-207.
28. Hoogduijn M.J., McGurk S., Smit N.P., Nibbering P.H., Ancans J., van der Laarse A., et al. Ligand-dependent activation of the melanocortin 5 receptor: cAMP production and ryanodine receptor-dependent elevations of [Ca(2+)](I). Biochem Biophys Res Commun 2002, 290:844-850.
29. Park H.J., Kim H.J., Lee J.Y., Cho B.K., Gallo R.L., Cho D.H. Adrenocorticotropin hormone stimulates interleukin-18 expression in human HaCaT keratinocytes. J Invest Dermatol 2007, 127:1210-1216.
30. Chai B., Li J.Y., Zhang W., Wang H., Mulholland M.W. Melanocortin-4 receptor activation inhibits c-Jun N-terminal kinase activity and promotes insulin signaling. Peptides 2009, 30:1098-1104.
31. Buggy J.J. Binding of alpha-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak/STAT pathway. Biochem J 1998, 331(Pt 1):211-216.
32. Daniels D., Patten C.S., Roth J.D., Yee D.K., Fluharty S.J. Melanocortin receptor signaling through mitogen-activated protein kinase in vitro and in rat hypothalamus. Brain Res 2003, 986:1-11.
33. Doyle J.R., Fortin J.P., Beinborn M., Kopin A.S. Selected melanocortin 1 receptor single-nucleotide polymorphisms differentially alter multiple signaling pathways. J Pharmacol Exp Ther 2012, 342:318-326.
34. Nijenhuis W.A., Oosterom J., Adan R.A. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. Mol Endocrinol 2001, 15:164-171.
35. Sanchez-Mas J., Hahmann C., Gerritsen I., Garcia-Borron J.C., Jimenez-Cervantes C. Agonist-independent, high constitutive activity of the human melanocortin 1 receptor. Pigm Cell Res/Sponsored by Eur Soc Pigm Cell Res Int Pigm Cell Soc 2004, 17:386-395.
36. Slominski A., Plonka P.M., Pisarchik A., Smart J.L., Tolle V., Wortsman J., et al. Preservation of eumelanin hair pigmentation in proopiomelanocortin-deficient mice on a nonagouti (a/a) genetic background. Endocrinology 2005, 146:1245-1253.
37. Krude H., Gruters A. Implications of proopiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocrinol Metab: TEM 2000, 11:15-22.
38. Mandrika I., Petrovska R., Wikberg J. Melanocortin receptors form constitutive homo- and heterodimers. Biochem Biophys Res Commun 2005, 326:349-354.
39. Nickolls S.A., Maki R.A. Dimerization of the melanocortin 4 receptor: a study using bioluminescence resonance energy transfer. Peptides 2006, 27:380-387.
40. Rediger A., Tarnow P., Bickenbach A., Schaefer M., Krude H., Gruters A., et al. Heterodimerization of hypothalamic G-protein-coupled receptors involved in weight regulation. Obes Facts 2009, 2:80-86.
41. Gao Z., Lei D., Welch J., Le K., Lin J., Leng S., et al. Agonist-dependent internalization of the human melanocortin-4 receptors in human embryonic kidney 293 cells. J Pharmacol Exp Ther 2003, 307:870-877.
42. Hopkins A.L., Mason J.S., Overington J.P. Can we rationally design promiscuous drugs. Curr Opin Struct Biol 2006, 16:127-136.
43. Ortega-Gomez A., Perretti M., Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med 2013, 5:661-674.
44. Sousa L.P., Alessandri A.L., Pinho V., Teixeira M.M. Pharmacological strategies to resolve acute inflammation. Curr Opin Pharmacol 2013, 13:625-631.
45. Bannenberg G.L., Chiang N., Ariel A., Arita M., Tjonahen E., Gotlinger K.H., et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005, 174:4345-4355.
46. Serhan C.N., Brain S.D., Buckley C.D., Gilroy D.W., Haslett C., O'Neill L.A., et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J: Off Pub Fed Am Soc Exp Biol 2007, 21:325-332.
47. Serhan C.N. The resolution of inflammation: the devil in the flask and in the details. FASEB J: Off Pub Fed Am Soc Exp Biol 2011, 25:1441-1448.
48. Gilroy D.W., Lawrence T., Perretti M., Rossi A.G. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004, 3:401-416.
49. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140:871-882.
50. Haringman J.J., Gerlag D.M., Smeets T.J., Baeten D., van den Bosch F., Bresnihan B., et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:2387-2392.
51. Rosser E.C., Oleinika K., Tonon S., Doyle R., Bosma A., Carter N.A., et al. Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production. Nat Med 2014, 20:1334-1339.
52. Jozic I., Stojadinovic O., Kirsner R.S., Tomic-Canic M. Stressing the steroids in skin: paradox or fine-tuning. J Invest Dermatol 2014, 134:2869-2872.
53. Ferrari W., Floris E., Paulesu F. [Eosinopenic effect of ACTH injected into the cisterna magna]. Boll Della Soc Ital Biol Speriment 1955, 31:859-862.
54. Star R.A., Rajora N., Huang J., Stock R.C., Catania A., Lipton J.M. Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone. Proc Natl Acad Sci U S A 1995, 92:8016-8020.
55. Catania A., Gerloni V., Procaccia S., Airaghi L., Manfredi M.G., Lomater C., et al. The anticytokine neuropeptide alpha-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases: comparisons with other anticytokine molecules. Neuroimmunomodulation 1994, 1:321-328.
56. Zaidi M., Sun L., Robinson L.J., Tourkova I.L., Liu L., Wang Y., et al. ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proc Natl Acad Sci U S A 2010, 107:8782-8787.
57. Cornish J., Callon K.E., Mountjoy K.G., Bava U., Lin J.M., Myers D.E., et al. Alpha-melanocyte-stimulating hormone is a novel regulator of bone. Am J Physiol Endocrinol Metab 2003, 284:E1181-E1190.
58. Grassel S., Opolka A., Anders S., Straub R.H., Grifka J., Luger T.A., et al. The melanocortin system in articular chondrocytes: melanocortin receptors, pro-opiomelanocortin, precursor proteases, and a regulatory effect of alpha-melanocyte-stimulating hormone on proinflammatory cytokines and extracellular matrix components. Arthritis Rheum 2009, 60:3017-3027.
59. Bohm M., Raghunath M., Sunderkotter C., Schiller M., Stander S., Brzoska T., et al. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem 2004, 279:6959-6966.
60. Bohm M., Grassel S. Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research. Endocr Rev 2012, 33:623-651.
61. Leoni G., Patel H.B., Sampaio A.L., Gavins F.N., Murray J.F., Grieco P., et al. Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion. FASEB J: Off Pub Fed Am Soc Exp Biol 2008, 22:4228-4238.
62. Leoni G., Voisin M.B., Carlson K., Getting S., Nourshargh S., Perretti M. The melanocortin MC(1) receptor agonist BMS-470539 inhibits leucocyte trafficking in the inflamed vasculature. Br J Pharmacol 2010, 160:171-180.
63. Scholzen T.E., Sunderkotter C., Kalden D.H., Brzoska T., Fastrich M., Fisbeck T., et al. Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology 2003, 144:360-370.
64. Getting S.J., Gibbs L., Clark A.J., Flower R.J., Perretti M. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J Immunol 1999, 162:7446-7453.
65. Montero-Melendez T., Patel H.B., Seed M., Nielsen S., Jonassen T.E., Perretti M. The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. Am J Pathol 2011, 179:259-269.
66. Bhardwaj R.S., Schwarz A., Becher E., Mahnke K., Aragane Y., Schwarz T., et al. Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. J Immunol 1996, 156:2517-2521.
67. Muffley L.A., Zhu K.Q., Engrav L.H., Gibran N.S., Hocking A.M. Spatial and temporal localization of the melanocortin 1 receptor and its ligand alpha-melanocyte-stimulating hormone during cutaneous wound repair. J Histochem Cytochem: Off J Histochem Soc 2011, 59:278-288.
68. Patel H.B., Bombardieri M., Sampaio A.L., D'Acquisto F., Gray M., Grieco P., et al. Anti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritis. FASEB J: Off Pub Fed Am Soc Exp Biol 2010, 24:4835-4843.
69. Kaneva M.K., Kerrigan M.J., Grieco P., Curley G.P., Locke I.C., Getting S.J. Chondroprotective and anti-inflammatory role of melanocortin peptides in TNF-alpha activated human C-20/A4 chondrocytes. Br J Pharmacol 2012, 167:67-79.
70. Manna S.K., Aggarwal B.B. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol 1998, 161:2873-2880.
71. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 2012, 8:122-128.
72. Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics: J Am Soc Exp NeuroTher 2013, 10:97-105.
73. Mapa J.B., Pillinger M.H. New treatments for gout. Curr Opin Investig Drugs 2010, 11:499-506.
74. H.P. Acthar® Gel. Repository corticotropin injection. Available at: [accessed October 2014]. http://www.acthar.com/pdf/Acthar-PI.pdf.
75. CORTROSYN (cosyntropin) injection, powder, lyophilized, for solution. Available at: [accessed October 2014]. http://dailymed.nlm.nih.gov/dailymed/search.cfm?query=cortrosyn.
76. Synacthen Depot Ampules. Tetracosactide acetate. Available at: [accessed October 2014]. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1411711038779.pdf.
77. Gettig J., Cummings J.P., Matuszewski K.H.p. Acthar gel and cosyntropin review: clinical and financial implications. P & T: Peer-Rev J Formulary Manage 2009, 34:250-257.
78. Miller H., Newell D.J., Ridley A. Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.). Lancet 1961, 2:1120-1122.
79. Khanna D., Khanna P.P., Fitzgerald J.D., Singh M.K., Bae S., Neogi T., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthrit Care Res 2012, 64:1447-1461.
80. Daoussis D., Antonopoulos I., Yiannopoulos G., Andonopoulos A.P. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine: Rev Rhumat 2013, 80:291-294.
81. Daoussis D., Antonopoulos I., Yiannopoulos G., Andonopoulos A.P. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine: Rev Rhumat 2014, 81:98-100.
82. Stafstrom C.E., Arnason B.G., Baram T.Z., Catania A., Cortez M.A., Glauser T.A., et al. Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol 2011, 26:1411-1421.
83. Cronstein B.N., Terkeltaub R. The inflammatory process of gout and its treatment. Arthrit Res Ther 2006, 8(Suppl. 1):S3.
84. Berkovich R., Agius M.A. Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis. Ther Adv Neurol Disord 2014, 7:83-96.
85. Loram L.C., Culp M.E., Connolly-Strong E.C., Sturgill-Koszycki S. Melanocortin peptides: potential targets in systemic lupus erythematosus. Inflammation 2015, 38:260-271.
86. Minder E.I. Afamelanotide for the treatment of erythropoietic protoporphyria. Expert Opin Orphan Drugs 2013, 1:341-349.
87. Sawyer T.K., Sanfilippo P.J., Hruby V.J., Engel M.H., Heward C.B., Burnett J.B., et al. 4-Norleucine, 7-d-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A 1980, 77:5754-5758.
88. Grieco P., Balse P.M., Weinberg D., MacNeil T., Hruby V.J. d-Amino acid scan of gamma-melanocyte-stimulating hormone: importance of Trp(8) on human MC3 receptor selectivity. J Med Chem 2000, 43:4998-5002.
89. Ma P., Zemmel R. Value of novelty. Nat Rev Drug Discov 2002, 1:571-572.
90. May L.T., Leach K., Sexton P.M., Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacool Toxicol 2007, 47:1-51.
91. Pantel J., Williams S.Y., Mi D., Sebag J., Corbin J.D., Weaver C.D., et al. Development of a high throughput screen for allosteric modulators of melanocortin-4 receptor signaling using a real time cAMP assay. Eur J Pharmacol 2011, 660:139-147.
92. Cone R.D. QnAs with Roger D. Cone. Proc Natl Acad Sci U S A 2013, 110:9618.
93. Grieco P., Cai M., Liu L., Mayorov A., Chandler K., Trivedi D., et al. Design and microwave-assisted synthesis of novel macrocyclic peptides active at melanocortin receptors: discovery of potent and selective hMC5R receptor antagonists. J Med Chem 2008, 51:2701-2707.
94. Kenakin T., Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 2013, 12:205-216.
95. Raehal K.M., Walker J.K., Bohn L.M. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 2005, 314:1195-1201.
96. Cai M., Stankova M., Pond S.J., Mayorov A.V., Perry J.W., Yamamura H.I., et al. Real time differentiation of G-protein coupled receptor (GPCR) agonist and antagonist by two photon fluorescence laser microscopy. J Am Chem Soc 2004, 126:7160-7161.
97. Nickolls S.A., Fleck B., Hoare S.R., Maki R.A. Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states. J Pharmacol Exp Ther 2005, 313:1281-1288.
98. Herraiz C., Jimenez-Cervantes C., Zanna P., Garcia-Borron J.C. Melanocortin 1 receptor mutations impact differentially on signalling to the cAMP and the ERK mitogen-activated protein kinase pathways. FEBS Lett 2009, 583:3269-3274.
99. Fitzgerald L.M., Fryer J.L., Dwyer T., Humphrey S.M. Effect of MELANOTAN, [Nle(4), d-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides 2006, 27:388-394.
100. Haslach E.M., Huang H., Dirain M., Debevec G., Geer P., Santos R.G., et al. Identification of tetrapeptides from a mixture based positional scanning library that can restore nM full agonist function of the L106P, I69T, I102S, A219V, C271Y, and C271R human melanocortin-4 polymorphic receptors (hMC4Rs). J Med Chem 2014, 57:4615-4628.